VEGFA and hereditary clear cell renal cell carcinoma: Based in part on the immunosuppressive effects of VEGF, antiangiogenic drugs (which target the VEGF pathway) combined with immune checkpoint inhibitors are been tested in numerous phase II and III clinical trials; some studies show an increase in immune infiltrates along with promising antitumor effects in melanoma [64, 65] and renal cell carcinoma [43, 66, 67].